Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.48 |
| ▸ | CTSL | P07711 | 11/20 | 0.48 |
| ▸ | CTSS | P25774 | 9/20 | 0.48 |
| ▸ | CTSB | P07858 | 4/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596974 | 0.88 | CTSK (0.55) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6214770 | 0.87 | CTSK (0.59) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6843765 | 0.84 | CTSK (0.56) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6837068 | 0.83 | SMN1; SMN2 (0.41) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6836885 | 0.81 | CTSK (0.41) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6213760 | 0.81 | CTSK (0.48) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6841344 | 0.80 | CTSK (0.39) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6836894 | 0.80 | CTSK (0.49) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6402928 | 0.79 | CTSK (0.46) | CTSKCTSLCTSSCTSBUTS2R | |
| SCHEMBL6842073 | 0.78 | CTSL (0.39) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSL 11/4885CTSS 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.